SG10201701780RA - Nucleophilic catalysts for oxime linkage - Google Patents
Nucleophilic catalysts for oxime linkageInfo
- Publication number
- SG10201701780RA SG10201701780RA SG10201701780RA SG10201701780RA SG10201701780RA SG 10201701780R A SG10201701780R A SG 10201701780RA SG 10201701780R A SG10201701780R A SG 10201701780RA SG 10201701780R A SG10201701780R A SG 10201701780RA SG 10201701780R A SG10201701780R A SG 10201701780RA
- Authority
- SG
- Singapore
- Prior art keywords
- oxime linkage
- nucleophilic catalysts
- nucleophilic
- catalysts
- oxime
- Prior art date
Links
- 239000012011 nucleophilic catalyst Substances 0.000 title 1
- 150000002923 oximes Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Water Supply & Treatment (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647814P | 2012-05-16 | 2012-05-16 | |
| US13/488,043 US8809501B2 (en) | 2009-07-27 | 2012-06-04 | Nucleophilic catalysts for oxime linkage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201701780RA true SG10201701780RA (en) | 2017-04-27 |
Family
ID=48579473
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201701780RA SG10201701780RA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| SG10201911328QA SG10201911328QA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| SG11201407597XA SG11201407597XA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911328QA SG10201911328QA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
| SG11201407597XA SG11201407597XA (en) | 2012-05-16 | 2013-05-16 | Nucleophilic catalysts for oxime linkage |
Country Status (12)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| MX2019005621A (es) * | 2016-11-14 | 2019-08-12 | Novartis Ag | Metodos y composiciones para el tratamiento del daño del cartilago y la artritis. |
| JP7002036B2 (ja) * | 2016-11-17 | 2022-01-20 | パナソニックＩｐマネジメント株式会社 | 膜電極接合体および固体酸化物形燃料電池 |
| US11786586B2 (en) | 2016-12-23 | 2023-10-17 | Aoa Dx | Carbohydrate structures and uses thereof |
| CN108503901B (zh) * | 2018-04-17 | 2020-07-07 | 哈尔滨工业大学 | 一种抗菌普鲁兰多糖/壳聚糖复合食品包装膜的制备方法 |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| US11767526B2 (en) | 2019-01-23 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| US11865134B2 (en) | 2021-02-26 | 2024-01-09 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors |
| JPWO2023171638A1 (enrdf_load_stackoverflow) | 2022-03-07 | 2023-09-14 | ||
| WO2025133203A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Compounds and methods for a long-lasting pam |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| ES2154650T3 (es) | 1992-10-02 | 2001-04-16 | Genetics Inst | Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador. |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| AU7097094A (en) * | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| US6531298B2 (en) | 1997-07-21 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Factor IX antihemophilic factor with increased clotting activity |
| US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| US6962972B2 (en) | 2000-05-16 | 2005-11-08 | Lipoxen Technologies Limited | Derivatization of proteins |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| KR100948532B1 (ko) | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | 분지형 중합체 및 그의 공액체 |
| CA2496317C (en) | 2002-09-11 | 2014-02-18 | Fresenius Kabi Deutschland Gmbh | Method of producing hydroxyalkyl starch derivatives |
| EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
| SI1620118T1 (sl) | 2003-04-08 | 2014-11-28 | Yeda Research And Development Co., Ltd. | Reverzibilna pegilirana zdravila |
| MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
| WO2005014024A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of a polymer and a protein linked by an oxime linking group |
| RU2333223C2 (ru) | 2003-08-12 | 2008-09-10 | Лайпоксен Текнолоджиз Лимитед | Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| NZ547554A (en) | 2003-12-03 | 2009-09-25 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| EP1776389B1 (en) | 2004-08-12 | 2016-06-29 | Lipoxen Technologies Limited | Sialic acid derivatives |
| WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| CN101163506B (zh) | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | 聚合物-von Willebrand因子偶联物 |
| EP1896082B1 (en) | 2005-06-16 | 2012-12-26 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| WO2008025856A2 (en) * | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Modified glycoproteins |
| PT2101821E (pt) | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
| MX2012001207A (es) * | 2009-07-27 | 2012-05-08 | Baxter Int | Conjugados proteicos de coagulacion sanguínea. |
| AU2010277438B2 (en) * | 2009-07-27 | 2015-08-20 | Baxalta GmbH | Glycopolysialylation of non-blood coagulation proteins |
| CN103370082A (zh) * | 2010-07-30 | 2013-10-23 | 巴克斯特国际公司 | 用于肟键联的亲核性催化剂 |
| KR101560541B1 (ko) * | 2012-04-13 | 2015-10-19 | 아우토리브 디벨롭먼트 아베 | 에어백 모듈과 스티어링 휠의 조립체 |
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
-
2013
- 2013-04-12 AU AU2013204754A patent/AU2013204754C1/en active Active
- 2013-05-16 EP EP21214357.2A patent/EP4019049A1/en active Pending
- 2013-05-16 BR BR112014028636-1A patent/BR112014028636B1/pt active IP Right Grant
- 2013-05-16 WO PCT/US2013/041300 patent/WO2013173557A1/en active Application Filing
- 2013-05-16 SG SG10201701780RA patent/SG10201701780RA/en unknown
- 2013-05-16 KR KR1020207013096A patent/KR102237306B1/ko active Active
- 2013-05-16 NZ NZ738846A patent/NZ738846A/en unknown
- 2013-05-16 EP EP13724491.9A patent/EP2849794A1/en not_active Withdrawn
- 2013-05-16 WO PCT/US2013/041280 patent/WO2013173543A1/en active Application Filing
- 2013-05-16 SG SG10201911328QA patent/SG10201911328QA/en unknown
- 2013-05-16 CN CN201811295900.8A patent/CN109620963B/zh active Active
- 2013-05-16 MX MX2014013919A patent/MX360594B/es active IP Right Grant
- 2013-05-16 CA CA2873756A patent/CA2873756C/en active Active
- 2013-05-16 EA EA201492115A patent/EA028186B9/ru not_active IP Right Cessation
- 2013-05-16 NZ NZ738844A patent/NZ738844A/en unknown
- 2013-05-16 EP EP13728026.9A patent/EP2849795B1/en active Active
- 2013-05-16 JP JP2015512831A patent/JP6195611B2/ja active Active
- 2013-05-16 SG SG11201407597XA patent/SG11201407597XA/en unknown
- 2013-05-16 KR KR1020217024432A patent/KR102326360B1/ko active Active
- 2013-05-16 KR KR1020147035113A patent/KR102110622B1/ko active Active
- 2013-05-16 CN CN201380037823.5A patent/CN104487095B/zh active Active
- 2013-05-16 EA EA201790935A patent/EA035506B1/ru not_active IP Right Cessation
- 2013-05-16 NZ NZ701945A patent/NZ701945A/en unknown
- 2013-05-16 KR KR1020217009701A patent/KR102287040B1/ko active Active
- 2013-05-16 NZ NZ724828A patent/NZ724828A/en unknown
-
2017
- 2017-06-01 JP JP2017109323A patent/JP6560712B2/ja active Active
-
2019
- 2019-02-05 JP JP2019018663A patent/JP6711935B2/ja active Active
-
2020
- 2020-04-03 JP JP2020067396A patent/JP7014844B2/ja active Active
-
2021
- 2021-12-29 JP JP2021215385A patent/JP7304402B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2514945B (en) | Catalyst blends | |
| AP2013007172A0 (en) | Catalyst | |
| GB201200831D0 (en) | Improved positioning system | |
| SG10201913078SA (en) | Nucleophilic catalysts for oxime linkage | |
| SG10201701780RA (en) | Nucleophilic catalysts for oxime linkage | |
| AU348420S (en) | Tyre | |
| PL2809297T3 (pl) | Nowy układ fotoochronny | |
| AU2013204754A1 (en) | Nucleophilic Catalysts for Oxime Linkage | |
| GB201410597D0 (en) | Improved vehicle | |
| EP2859438A4 (en) | OPERATING SYSTEM | |
| GB201416097D0 (en) | Handle for vehicle | |
| GB201220691D0 (en) | A catalyst | |
| AP2013007004A0 (en) | Catalysts | |
| GB2508511B (en) | Bimetallic catalyst | |
| PT2844110T (pt) | Mecanismo para beliches dobráveis | |
| GB2504567B (en) | Anti-Relatch Mechanism | |
| GB201202393D0 (en) | Polymorphs | |
| PL2677287T3 (pl) | Pomocnicze wyposażenie do ważenia | |
| HUE040533T2 (hu) | Terményemelõ | |
| GB201201259D0 (en) | Cover members | |
| GB2488127B (en) | Operation system for umbrellas | |
| GB201319664D0 (en) | Formwork for steps | |
| GB201220529D0 (en) | No details available | |
| GB201120594D0 (en) | Catalyst compounds | |
| AU4908P (en) | X115-32-5 Gomphrena leontopodioides |